Genmab — Juni 2023
-
Epcoritamab Plus Rituximab/Lenalidomide Produces Responses in High-risk R/R Follicular Lymphoma https://www.onclive.com/view/epcoritamab-plus-rituximab-lenalidomide-produces-responses-in-high-risk-r-r-follicular-lymphoma (this was the oral presentation)
-
Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.7506?af=R
-
easier article maybe - Positive Responses Seen in Follicular Lymphoma When Epcoritamab Is Added to Rituximab and Lenalidomide https://dailynews.ascopubs.org/do/positive-responses-seen-follicular-lymphoma-epcoritamab-added-rituximab-and
-
Godmorgen

-
Shortpositioner på danske aktier https://www.proinvestor.com/boards/113022
-
Ja spændende hvornår turen op til 3500 starter...;-)
-
Ok...så mangler der jo "kun" ca. 600:-)
-
Kort video: Gevinsthjemtagning i Novo, Zealand Pharma og Genmab : https://www.proinvestor.com/boards/113030
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind